EDEX (alprostadil) by R-Pharm US is prostaglandin receptor agonists [moa]. First approved in 1997.
Drug data last refreshed 18h ago · AI intelligence enriched 5d ago
EDEX (alprostadil) is a prostaglandin receptor agonist administered by injection for the treatment of erectile dysfunction. It works by dilating blood vessels and relaxing smooth muscle to increase blood flow to the penis. This small-molecule injectable represents a mechanistic alternative to phosphodiesterase inhibitors.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating contracting market opportunity and smaller team requirements.
Prostaglandin Receptor Agonists
Prostaglandin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn About the Study Medicine - Precedex in Children From Japan.
Precedex Special Investigation (in Pediatric Patients)
Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study
Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients
Cerebral Perfusion Pressure Using Precedex and Other Sedatives
Worked on EDEX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
EDEX currently has zero linked job postings, reflecting its approaching loss-of-exclusivity stage and mature market position. Roles on this product focus on defensive market maintenance and patient access rather than growth-oriented activities.